Overview


According to FutureWise analysis the market for japan cancer vaccines is expected to register a CAGR of 18.42% from 2023-2031.

FutureWise Market Research has instantiated a report that provides an intricate analysis of Japan Cancer Vaccines Market trend that shall affect the overall market growth. Furthermore, it includes detailed information on the graph of profitability, SWOT analysis, market share and regional proliferation of this business. Moreover, the report offers insights on the current stature of prominent market players in the competitive landscape analysis of this market.

According to the research study conducted by FutureWise research analysts, the Japan Cancer Vaccines Market is anticipated to attain substantial growth by the end of the forecast period. The report explains that this business is predicted to register a noteworthy growth rate over the forecast period. This report provides crucial information pertaining to the total valuation that is presently held by this industry and it also lists the segmentation of the market along with the growth opportunities present across this business vertical.

  • Aduro BioTech, Inc.
  • Daiichi Sankyo Company
  • Otsuka Pharmaceutical Co., Ltd.,
  • Astellas Pharma, Inc.
  • AstraZeneca PLC
  • Bristol-Myers Squibb
  • GlaxoSmithKline
  • MerckCo., Inc.
  • Oncolys BioPharma Inc
  • CYTLIMIC
  • BrightPath Biotherapeutics
  • Takeda Pharmaceutical Company Limited
  • Takara Bio
  • tella,Inc.
  • Boston Biomedical (acquired by Dainippon Sumitomo Pharma Co., Ltd: DSP)
  • ImmunoFrontier, Inc.
  • OncoTherapy Science, Inc.

(Note: The list of the major players will be updated with the latest market scenario and trends)

By Type

  • Prevention Vaccines
    • HPV
    • HBV
  • Treatment Vaccines
    • Antigen Vaccines
    • Dendritic Cell Vaccines
    • DNA Vaccines
    • Whole Tumour Vaccines
    • Anti-Idiotype Vaccines
  • Oncolytic Viruses

By Indication

  • Prostate
  • Cervical
  • Others

By Patient Type

  • Pediatric
  • Adults
  • Tier 1 players- established companies in the market with a major market share
  • Tier 2 players
  • Emerging players which are growing rapidly
  • New Entrants
  • Growth prospects
  • SWOT analysis
  • Key trends
  • Key data-points affecting market growth
  • To provide with an exhaustive analysis on the Japan Cancer Vaccines Market By Type, By Indication and By Patient Type.
  • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
  • To evaluate and forecast micro-markets and the overall market
  • To predict the market size, in key regions—Japan
  • To record and evaluate competitive landscape mapping- product launches, technological advancements, mergers and expansions
  • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
  • The customisation offered are free of charge with purchase of any license of the report
  • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents


  • 1.   Market Introduction
    •   1. Objectives of the Study
        2. Market Definition
        3. Market Scope
         3.1. Years Considered for the Study
         3.2. Market Covered
        4. Currency
        5. Limitations
        6. Stakeholders

  • 2.   Research Methodology
    •   1. Research Data
         1.1. Secondary Data
          1.1.1. Key Data from Secondary Sources
         1.2. Primary Data
          1.2.1. Key Data from Primary Sources
        2. Market Size Estimation
        3. Market Breakdown and Data Triangulation
        4. Assumptions for the Study

  • 3.   Executive Summary
    •   1. Market Outlook
        2. Segment Outlook
        3. Competitive Insights
  • 4.   Japan Cancer Vaccines Market Variables, Trends and Scope
    •   1. Market Lineage Outlook
        2. Penetration and Growth Prospect Mapping
        3. Industry Value Chain Analysis
        4. Cost Analysis Breakdown
        5. Product Overview
        6. Regulatory Framework
         6.1. Reimbursement Framework
         6.2. Standards and Compliances

  • 5.   Market Overview
    •   1. Market Dynamics
         1.1. Market Driver Analysis
          1.1.1. Increasing focus of Companies on Brand Protection
          1.1.2. Untapped Opportunities in Emerging Regions
         1.2. Market Restraint Analysis
          1.2.1. High Cost Associated with Implementation of Predictive Analysis
         1.3. Industry Challenges
          1.3.1. Presence of Ambiguous Regulatory Framework
  • 6.   Japan Cancer Vaccines Market Analysis Tools
    •   1. Industry Analysis - Porter’s
         1.1. Supplier Power
         1.2. Buyer Power
         1.3. Substitution Threat
         1.4. Threat from New Entrants
         1.5. Competitive Rivalry
        2. Pestel Analysis
         2.1. Political Landscape
         2.2. Environmental Landscape
         2.3. Social Landscape
         2.4. Product Landscape
         2.5. Legal Landscape
        3. Major Deals And Strategic Alliances Analysis
         3.1. Joint Ventures
         3.2. Mergers and Acquisitions
         3.3. Licensing and Partnership
         3.4. Product Collaborations
         3.5. Strategic Divestments
        4. Market Entry Strategies
        5. Case Studies
  • 7.   Japan Cancer Vaccines Market, By Type Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Prevention Vaccines
         1.1. HPV
         1.2. HBV
        2. Treatment Vaccines
         2.1. Antigen Vaccines
         2.2. Dendritic Cell Vaccines
         2.3. DNA Vaccines
         2.4. Whole Tumour Vaccines
         2.5. Anti-Idiotype Vaccines
        3. Oncolytic Viruses

  • 8.   Japan Cancer Vaccines Market, By Indication Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Prostate
        2. Cervical
        3. Others

  • 9.   Japan Cancer Vaccines Market, by Patient Type Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Pediatric
        2. Adults

  • 10.   Japan Cancer Vaccines Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis, 2017-2022
        3. Market Size (USD Million) Forecast for Japan 2023-2031

  • 11.   Market Share Analysis and Competitive Landscape
    •   1. Key Players, Revenue and Presence
        2. Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
        3. Emerging Companies
        4. Japan Market Share Analysis and Key Regional Players
        5. Key Player - Growth Matrix
  • 12.   Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts)
    •   1. Aduro BioTech, Inc.
         1.1. Company Overview
         1.2. Product Portfolio
         1.3. SWOT Analysis
         1.4. Financial Overview
         1.5. Strategic Overview
        2. Daiichi Sankyo Company
         2.1. Company Overview
         2.2. Product Portfolio
         2.3. SWOT Analysis
         2.4. Financial Overview
         2.5. Strategic Overview
        3. Otsuka Pharmaceutical Co., Ltd.,
         3.1. Company Overview
         3.2. Product Portfolio
         3.3. SWOT Analysis
         3.4. Financial Overview
         3.5. Strategic Overview
        4. Astellas Pharma, Inc.
         4.1. Company Overview
         4.2. Product Portfolio
         4.3. SWOT Analysis
         4.4. Financial Overview
         4.5. Strategic Overview
        5. AstraZeneca PLC
         5.1. Company Overview
         5.2. Product Portfolio
         5.3. SWOT Analysis
         5.4. Financial Overview
         5.5. Strategic Overview
        6. Bristol-Myers Squibb
         6.1. Company Overview
         6.2. Product Portfolio
         6.3. SWOT Analysis
         6.4. Financial Overview
         6.5. Strategic Overview
        7. GlaxoSmithKline
         7.1. Company Overview
         7.2. Product Portfolio
         7.3. SWOT Analysis
         7.4. Financial Overview
         7.5. Strategic Overview
        8. MerckCo., Inc.
         8.1. Company Overview
         8.2. Product Portfolio
         8.3. SWOT Analysis
         8.4. Financial Overview
         8.5. Strategic Overview
        9. Oncolys BioPharma Inc
         9.1. Company Overview
         9.2. Product Portfolio
         9.3. SWOT Analysis
         9.4. Financial Overview
         9.5. Strategic Overview
        10. CYTLIMIC
         10.1. Company Overview
         10.2. Product Portfolio
         10.3. SWOT Analysis
         10.4. Financial Overview
         10.5. Strategic Overview
        11. BrightPath Biotherapeutics
         11.1. Company Overview
         11.2. Product Portfolio
         11.3. SWOT Analysis
         11.4. Financial Overview
         11.5. Strategic Overview
        12. Takeda Pharmaceutical Company Limited
         12.1. Company Overview
         12.2. Product Portfolio
         12.3. SWOT Analysis
         12.4. Financial Overview
         12.5. Strategic Overview
        13. Takara Bio
         13.1. Company Overview
         13.2. Product Portfolio
         13.3. SWOT Analysis
         13.4. Financial Overview
         13.5. Strategic Overview
        14. tella,Inc.
         14.1. Company Overview
         14.2. Product Portfolio
         14.3. SWOT Analysis
         14.4. Financial Overview
         14.5. Strategic Overview
        15. Boston Biomedical (acquired by Dainippon Sumitomo Pharma Co., Ltd: DSP)
         15.1. Company Overview
         15.2. Product Portfolio
         15.3. SWOT Analysis
         15.4. Financial Overview
         15.5. Strategic Overview
        16. ImmunoFrontier, Inc.
         16.1. Company Overview
         16.2. Product Portfolio
         16.3. SWOT Analysis
         16.4. Financial Overview
         16.5. Strategic Overview
        17. OncoTherapy Science, Inc
         17.1. Company Overview
         17.2. Product Portfolio
         17.3. SWOT Analysis
         17.4. Financial Overview
         17.5. Strategic Overview

  • 13.   Pre and Post COVID-19 Impact
    •   1. Positive influence on the healthcare industry
        2. The financial disruption of the manufacturing sector
        3. Impact of COVID-19 on emerging companies
        4. Significant mandates in the healthcare regulations initiated
      by administrations
        5. The overall economic slowdown of the developing and developed nations

  • 14.   FutureWise SME Key Takeaway Points for Client
Partner

Our Clients